AbbVie announced FDA approval of JUVMO™ (tavapadon), the first selective D1/D5 receptor agonist for treating adults with Parkinson's disease. JUVMO offers a novel approach to motor symptom control, improving daily functioning and increasing 'on' time without troublesome dyskinesia, as shown in Phase 3 TEMPO trials. It can be taken once daily, with or without levodopa, and may reduce the need for levodopa dose increases. AbbVie plans to make JUVMO available in the U.S. by October 2026, providing a new treatment option that addresses limitations of existing dopamine agonists targeting D2/D3 receptors.
AbbVie's stock price is currently at USD 264.29 on Pluang, showing a slight 0.04% decrease. As of Sep 28, 2026 19:18 WIB, the company holds a market cap of $467.12 billion with a dividend yield of 2.62%.
